Price
53.61
-2.89%52W Range
Market Cap
₹115.59 Cr
Traded: ₹0.02 Cr (0.02%) 0.0x
Free Float: ₹21.26 Cr (0.10% of FF traded)
Volume · 60D trend
3.88 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +35.0% | -15.0% | -23.0% | -- | -30.0% | Decelerating |
| ROE | -- | -- | -- | -- | -- | -- |
| Return | -3.0% | -16.0% | -8.0% | -29.0% | -- | Stable |
| Profit | +0.0% | +7.0% | +10.0% | -- | +48.0% | Accelerating |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7 | 7 | 7 | 4 | 5 | 6 | 11 | 13 | 13 | 12 | 13 | 15 | 11 | 11 |
| Expenses | 6 | 8 | 7 | 7 | 8 | 12 | 16 | 16 | 15 | 15 | 15 | 16 | 13 | 16 |
| Operating Profit | 1 | -1 | 0 | -3 | -2 | -5 | -5 | -3 | -2 | -3 | -2 | -1 | -3 | -5 |
| OPM % | 11.8% | -12.6% | 4.1% | -67.2% | -38.1% | -88.7% | -41.1% | -21.1% | -17.0% | -26.1% | -16.1% | -6.0% | -24.8% | -40.3% |
| Other Income | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 |
| Profit Before Tax | -2 | -2 | -3 | -6 | -5 | -8 | -8 | -6 | -5 | -6 | -5 | -4 | -5 | -7 |
| Tax % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Profit | -2 | -2 | -3 | -6 | -5 | -8 | -8 | -6 | -5 | -6 | -5 | -4 | -5 | -7 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | -1.1 | -1.1 | -1.4 | -2.9 | -2.5 | -3.8 | -3.6 | -2.7 | -2.4 | -2.7 | -2.3 | -1.7 | -2.5 | -3.2 |
| Sales Growth (YoY) | 27.4% | 11.6% | -36.6% | -67.6% | -57.5% | -49.0% | -11.6% | -13.6% | 21.8% | 4.5% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 2.5% | -6.3% | 74.3% | -23.9% | -10.2% | -46.8% | -10.8% | -0.2% | 7.7% | -7.8% | -12.8% | 40.7% | -7.7% | -- |
| OP Growth (YoY) | 139.2% | 84.1% | 106.4% | -2.9% | 4.6% | -73.4% | -125.4% | -202.2% | 16.4% | 32.5% | -- | -- | -- | -- |
| OP Growth (QoQ) | 195.3% | -386.7% | 110.7% | -34.0% | 61.4% | -14.9% | -73.2% | -24.2% | 29.8% | -49.3% | -132.2% | 65.6% | 43.3% | -- |
| Profit Growth (YoY) | 53.0% | 72.0% | 60.0% | -7.0% | -3.0% | -41.0% | -55.0% | -61.0% | 3.0% | 16.0% | 10.0% | 12.0% | 35.0% | 39.0% |
| EPS Growth (YoY) | 53.4% | 71.6% | 59.6% | -6.7% | -2.9% | -41.7% | -55.4% | -60.8% | 2.8% | 15.8% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -5.5% | 24.8% | 49.1% | -15.4% | 35.7% | -7.0% | -34.5% | -11.3% | 11.4% | -17.3% | -39.2% | 32.8% | 23.3% | -- |
| OP Margin | 11.8% | -12.6% | 4.1% | -67.2% | -38.1% | -88.7% | -41.1% | -21.1% | -17.0% | -26.1% | -16.1% | -6.0% | -24.8% | -40.3% |
| Net Margin | -35.5% | -34.4% | -43.0% | -147.2% | -97.1% | -135.6% | -67.5% | -44.8% | -40.1% | -48.9% | -38.4% | -24.0% | -50.4% | -60.6% |
| Material Cost % | -- | 1.5% | 0.0% | 0.0% | 5.3% | 9.3% | 11.4% | 18.8% | 9.8% | 24.2% | 9.9% | 13.8% | 3.5% | 27.5% |
| Employee Cost % | -- | 33.0% | 37.0% | 64.5% | 50.2% | 56.6% | 39.2% | 34.1% | 33.0% | 32.4% | 34.2% | 27.5% | 38.4% | 39.4% |
| P/S | 4.58 | 4.92 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50The Company has enclosed herewith copy of newpapers advertiesment of unaudited financial results for the quarter ended 30.06.2026
Results for the quarter ended 30602026
Outcome of BM
The Company has enclosing herewith Certficate recived from RTA under Reg 74 (5) of DP Regulations, 2018 for the quarter ended 31.06.2026.
Outcome of Board Meeting
outcome of Baorad meeting
The Company has enclosed herewith intimation for closure of trading window for the quareter ended 30.06.2026
The Company has enclosed herewith Annual Secretarial Complince Report for the yaer ended 31.03.2026.
The Company has enclosing herewith copy of newspapers advetiement of financial resulst for the quarter and yaer ended 31.03.2026.
Outcome of Board Meeting 21.05.2026
Audited Results for fiancial yaer ended 31.03.2026
Krebs Biochemicals & Industries Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve Pursuant to ....
Clarification on price movement
The Exchange has sought clarification from Krebs Biochemicals & Industries Ltd on April 8, 2026 with reference to significant movement in price, in order to ensure that investors have latest ....
The Company has enclosing herewith certificate received from RTA under reg 74 (5) of SEBI DP Regulations, 2018 for the quarter ended 31.03.2026.
The Company has enclosinh herewith intimation for closure of trading window for considaration of audited financial results for the 4th quarter and year ended 31.03.2026.
The Company has enclosing copy of newspaper advertisement of financial results for the quarter ended 31.12.2025
Result for the quarter ended 31.12.2025
Outcome of Board Meeting
Krebs Biochemicals & Industries Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026 ,inter alia, to consider and approve Board Meeting ....
The Company has enclosed herewith report on relodgement of shares for the month of December 2025.
The Company has enclosing herewith certificate recived from RTA under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31.12.2025.
The Company has enclosed herewith intimation for closing of trading window for the quarter ended 31.12.2025
The Company enclosing herewith RTA report on relodgement of trasnfer request of physical shares for the month Nov 2025.
The Company has enclosed herewith re-lodgement certificate received from RTA.
The Company has enclosed herewith copy of newspapers advertisement for financial results for the quarter and half year ended 30.09.2025
Outcome
Result Sept 2025
Krebs Biochemicals & Industries Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2025 ,inter alia, to consider and approve The Company ....
The Company has received Certificate for Re lodgment of physical shares for the month of Sept 2025.
The Company has enclosed herewith certificate received from RTA for the quarter ended 30.09.2025.
The Company has enclosing herewith voting result and scrutinizer report for 33 rd AGM
The Company has enclosed herewith proceedings of 33rd Annual General Meeting of the Company.
The Company has enclosed herewith intimation of closure of trading window for quarter and half year ended 30.09.2025
The Company has enclosed herewith RTA Report on re-lodgement of transfer requests of physical shares for the period up to 31.08.2025.
The Company has enclosed herewith copy of newspapers published in business standard and prajasakti w.r.t. Notice of 33rd Annual General Meeting.
The Company has enclosed herewith notice of 33rd Annual General Meeting of the Company.
The Company has enclosed herewith copy of Annual Report for the financial year ended 31st March 2025.
The Company has enclosed herewith copy of newspaper publication of unaudited financial results for the quarter ended 30.06.2025.
The Company has enclosed herewith comments of Board on fine levied by Exchanges
Intimation respect to change in management
result
Outcome of Board meeting dated 07.08.2025
The Company has enclosing herewith resignation letter received from Mr. Jitendra Shah Managing Director & CEO
Krebs Biochemicals & Industries Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2025 ,inter alia, to consider and approve The Company ....
The Company has enclosed herewith certificates received from RTA under reg. 74(5) of SEBI DP Regulations, 2018 for the quarter ended 31.03.2025
The Company has enclosed herewith intimation for closure of trading window for the quarter ended 30th June 2025.
The Company has enclosing herewith Annual Secretarial Compline Report for the year ended 31st March 2025.
The Company has enclosing herewith copy of newspaper publication.
Result for the year ended 31.03.2025